1. C1‐INH concentrate for treatment of acute hereditary angioedema: a pediatric cohort from the I.M.P.A.C.T. studies. Issue 1 (22nd November 2012) Authors: Schneider, Lynda; Hurewitz, David; Wasserman, Richard; Obtulowicz, Krystyna; Machnig, Thomas; Moldovan, Dumitru; Reshef, Avner; Craig, Timothy J. Journal: Pediatric allergy and immunology Issue: Volume 24:Issue 1(2013) Page Start: 54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema. Issue 6 (11th May 2021) Authors: Farkas, Henriette; Reshef, Avner; Caballero, Teresa; Ortega López, María C.; Kessel, Aharon; Vardi, Moshe; Hao, James; Aberer, Werner Editors: Atanaskovic‐Markovic, Marina Journal: Pediatric allergy and immunology Issue: Volume 32:Issue 6(2021) Page Start: 1392 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Definition, aims, and implementation of GA2LEN/HAEi Angioedema Centers of Reference and Excellence. Issue 8 (27th April 2020) Authors: Maurer, Marcus; Aberer, Werner; Agondi, Rosana; Al‐Ahmad, Mona; Al‐Nesf, Maryam Ali; Ansotegui, Ignacio; Arnaout, Rand; Arruda, Luisa Karla; Asero, Riccardo; Aygören‐Pürsün, Emel; Banerji, Aleena; Bauer, Andrea; Ben‐Shoshan, Moshe; Berardi, Alejandro; Bernstein, Jonathan A.; Betschel, Stephen; Bi... Journal: Allergy Issue: Volume 75:Issue 8(2020) Page Start: 2115 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Issue 10382 (1st April 2023) Authors: Craig, Timothy J; Reshef, Avner; Li, H Henry; Jacobs, Joshua S; Bernstein, Jonathan A; Farkas, Henriette; Yang, William H; Stroes, Erik S G; Ohsawa, Isao; Tachdjian, Raffi; Manning, Michael E; Lumry, William R; Saguer, Inmaculada Martinez; Aygören-Pürsün, Emel; Ritchie, Bruce; Sussman, Gordon L; ... Journal: Lancet Issue: Volume 401:Issue 10382(2023) Page Start: 1079 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study. Issue 4 (18th June 2021) Authors: Farkas, Henriette; Stobiecki, Marcin; Peter, Jonny; Kinaciyan, Tamar; Maurer, Marcus; Aygören‐Pürsün, Emel; Kiani‐Alikhan, Sorena; Wu, Adrian; Reshef, Avner; Bygum, Anette; Fain, Olivier; Hagin, David; Huissoon, Aarnoud; Jeseňák, Miloš; Lindsay, Karen; Panovska, Vesna Grivcheva; Steiner, Urs C.; ... Journal: Clinical and translational allergy Issue: Volume 11:Issue 4(2021) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. New medications to mitigate attacks of hereditary angioedema: does one size fit all?. Issue 10375 (11th February 2023) Authors: Reshef, Avner; Grumach, Anete S Journal: Lancet Issue: Volume 401:Issue 10375(2023) Page Start: 413 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Prodromes as predictors of hereditary angioedema attacks. Issue 4 (15th January 2022) Authors: Leibovich‐Nassi, Iris; Reshef, Avner; Somech, Raz; Golander, Hava Journal: Allergy Issue: Volume 77:Issue 4(2022) Page Start: 1309 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Prodromes predict attacks of hereditary angioedema: Results of a prospective study. Issue 2 (29th October 2022) Authors: Leibovich‐Nassi, Iris; Golander, Hava; Reshef, Avner Journal: Allergy Issue: Volume 78:Issue 2(2023) Page Start: 577 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial. Issue 10328 (5th March 2022) Authors: Craig, Timothy; Magerl, Markus; Levy, Donald S; Reshef, Avner; Lumry, William R; Martinez-Saguer, Inmaculada; Jacobs, Joshua S; Yang, William H; Ritchie, Bruce; Aygören-Pürsün, Emel; Keith, Paul K; Busse, Paula; Feuersenger, Henrike; Pawaskar, Dipti; Jacobs, Iris; Pragst, Ingo; Doyle, Mittie K Journal: Lancet Issue: Volume 399:Issue 10328(2022) Page Start: 945 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Issue 10102 (30th September 2017) Authors: Riedl, Marc A; Grivcheva-Panovska, Vesna; Moldovan, Dumitru; Baker, James; Yang, William H; Giannetti, Bruno M; Reshef, Avner; Andrejevic, Sladjana; Lockey, Richard F; Hakl, Roman; Kivity, Shmuel; Harper, Joseph R; Relan, Anurag; Cicardi, Marco Journal: Lancet Issue: Volume 390:Issue 10102(2017) Page Start: 1595 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗